(Boursier.com) — DMS-Group recorded in 2021 an EBITDA of 1.9 ME, a marked increase compared to 2020 when this balance was just at equilibrium. The 2021 EBITDA margin stands at 5.1%. After taking into account net allocations to amortization and provisions, up due to the amortization of new R&D projects and the new building in Gallargues-le-Montueux, current operating income stands at -0.8 M, an improvement +1.6 ME from one fiscal year to the next. Other operating income and expenses amounted to -2.8 ME, consisting of costs and fees related to the acquisition of Asit biotech in 2021 and fixed asset depreciation related to the termination of an R&D project on the Stemcis subsidiary within the DMS Biotech division. After accounting for a financial result of -0.4 ME, the net result group share for 2021 stands at -3.9 ME, an improvement of +1.4 ME compared to the previous financial year.
The EBITDA of the DMS Imaging division reached a record amount of 2.5 ME in 2021, almost double compared to the 2020 financial year (1.3 ME). The EBITDA margin thus fell from 4.2% in 2020 to 6.8% in 2021.
In the wake of the sustained growth of 2021, DMS Group got off to a good start in the new financial year with a turnover of 8.9 ME in the 1st quarter of 2022, a level of activity comparable to that achieved in the 4th quarter of 2021 and stable compared to in the 1st quarter of 2021 which had been marked by a high level of invoicing for the Radiology activity linked to the delivery of a major contract as part of a World Bank call for tenders during the period. In bone densitometry, activity was very dynamic at the start of the financial year (+57% growth in the 1st quarter of 2022), with a ramping up of exports and the commercial contract with Fujifilm.
Tensions in terms of supply, particularly for certain electronic components or equipment, nevertheless remained particularly acute at the start of 2022 but only caused moderate impacts in the 1st quarter of 2022, thanks to the agility of the purchasing teams. , supply chain and production of the group. In imaging, DMS Group emphasizes that 2022 will see the development of partnerships with Fujifilm, in the United States as well as in the Africa and Middle East region following the extension of the Platinum radiology table distribution agreement. DRF Adam. The first model of the new Platinum Neo radiology table, based on a software platform with the ability to embed machine intelligence and eventually artificial intelligence (AI) functionalities, was delivered at the end of 1st trimester. Its international deployment will accelerate during the second half of 2022.
©2022 Boursier.com